Novel assay for ubiquitin pathway enzymes as biomarkers

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43MH082470-01A1
Agency Tracking Number: MH082470
Amount: $267,299.00
Phase: Phase I
Program: SBIR
Awards Year: 2008
Solicitation Year: 2008
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Small Business Information
LIFESENSORS, INC.
LIFESENSORS, INC., 271 GREAT VALLEY PKY, MALVERN, PA, 19355
DUNS: 060013641
HUBZone Owned: Y
Woman Owned: Y
Socially and Economically Disadvantaged: Y
Principal Investigator
 () -
Business Contact
Phone: (610) 644-8845
Email: butt@lifesensors.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): It has been well established that the ubiquitin pathway plays an important role as a key regulator of neuronal biology. The ubiquitin pathway enzymes are essential and critical mediators of synaptic adaptability in matu re neurons, and dysfunctional ubiquitin pathway enzymes or regulation is associated with diverse neurodegenerative disorders. Deubiquitinating enzymes, or DUBs belong to a family of ~100 primarily single subunit proteins that remove ubiquitin from lysine r esidues of target proteins. Evidence suggests that that dysregulated or un-regulated DUB(s) can lead to neurodegenerative disease. Most commonly used assays for DUB activity are not suitable for either clinical applications or drug discovery. In this propo sal, a novel assay for the DUB family of proteins will be developed. The assay involves a semi-synthetic approach to develop reagents that are extensions of the C-terminus of ubiquitin that is conjugated to target proteins. A library of peptides can be ext ended from the C-terminus of ubiquitin; the best reagent for a given DUB can be selected from the library since classes of DUBs show different specificity preferences. In contrast to their fate in solution phase assays, entities cleaved by DUBs will be imm obilized on a surface, allowing them to be suitable reagents for immobilized DUBs in a multiplex environment. Since the assay can identify a protein as a DUB, it can also uncover DUB interactive proteins or the accumulation of ubquitinated substrates commo n in neurodegenerative diseases. Thus, the assay will be useful for diagnostic as well as drug discovery purposes. In Phase II, the assay will be expanded to include all known DUBs. The commercial application of this technology is the generation of product s for diagnostic and therapeutic uses as applied to DUB-linked medical needs such as neurodegenerative diseases. Proteins modified by another small protein called ubiquitin are key regulators of neuronal biology. Enzymes that catalyse the addition or remov al of ubiquitin to target proteins are important regulators of neuronal cell function and are potentially useful for diagnosing various neurological diseases or discovering drugs to treat the diseases. PUBLIC HEALTH RELEVANCE: LifeSensors proposes to devel op an assay for one of the major types of ubiquitin pathway enzymes known as DUBs (deubiquitinating enzymes). This assay represents a novel technology that will have potential utility in diagnostics and in the discovery of potent and selective drugs to tre at Alzheimer's Disease and other neurological diseases.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government